Jeffrey J Tomaszewski1, Erin L Richman2, Natalia Sadetsky3, Denise S O'Keefe4, Peter R Carroll3, Benjamin J Davies5, June M Chan6. 1. Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: tomaszewski.jeffrey@gmail.com. 2. Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California. 3. Department of Urology, University of California-San Francisco, San Francisco, California. 4. Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 5. Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California; Department of Urology, University of California-San Francisco, San Francisco, California.
Abstract
PURPOSE: A randomized, placebo controlled clinical trial of folic acid supplementation for the chemoprevention of colorectal adenoma revealed an increased incidence of prostate cancer in the treatment group. Limited data exist on postdiagnostic folate/folic acid intake and the risk of prostate cancer progression. We prospectively examined the association between postdiagnostic folate consumption and the risk of prostate cancer recurrence after radical prostatectomy, external beam radiation therapy and brachytherapy. MATERIALS AND METHODS: This study was done in 1,153 men treated with radical prostatectomy, external beam radiation therapy and brachytherapy who had clinical stage T1-T2c prostate adenocarcinoma and participated in the CaPSURE Diet and Lifestyle substudy by completing the semiquantitative Food Frequency Questionnaire in 2004 to 2005. We used Cox proportional hazards regression to analyze the association between folate intake and prostate cancer progression. RESULTS: Prostate cancer progressed in 101 men (8.76%) during a mean 34-month followup. After multivariate adjustment we observed no evidence of an association of the intake of total folate, dietary folate or dietary folate equivalents with prostate cancer recurrence. On secondary analysis by treatment after radical prostatectomy patients in the lowest decile of dietary folate intake had a 2.6-fold increase in the risk of recurrence (HR 2.56, 95% CI 1.23-5.29, p = 0.01). In patients treated with external beam radiation and brachytherapy we observed no evidence of an association between prostate cancer progression and increased folate intake. CONCLUSIONS: Results suggest that the consumption of foods and multivitamins that contain folate is not associated with prostate cancer progression after definitive treatment.
PURPOSE: A randomized, placebo controlled clinical trial of folic acid supplementation for the chemoprevention of colorectal adenoma revealed an increased incidence of prostate cancer in the treatment group. Limited data exist on postdiagnostic folate/folic acid intake and the risk of prostate cancer progression. We prospectively examined the association between postdiagnostic folate consumption and the risk of prostate cancer recurrence after radical prostatectomy, external beam radiation therapy and brachytherapy. MATERIALS AND METHODS: This study was done in 1,153 men treated with radical prostatectomy, external beam radiation therapy and brachytherapy who had clinical stage T1-T2c prostate adenocarcinoma and participated in the CaPSURE Diet and Lifestyle substudy by completing the semiquantitative Food Frequency Questionnaire in 2004 to 2005. We used Cox proportional hazards regression to analyze the association between folate intake and prostate cancer progression. RESULTS:Prostate cancer progressed in 101 men (8.76%) during a mean 34-month followup. After multivariate adjustment we observed no evidence of an association of the intake of total folate, dietary folate or dietary folate equivalents with prostate cancer recurrence. On secondary analysis by treatment after radical prostatectomy patients in the lowest decile of dietary folate intake had a 2.6-fold increase in the risk of recurrence (HR 2.56, 95% CI 1.23-5.29, p = 0.01). In patients treated with external beam radiation and brachytherapy we observed no evidence of an association between prostate cancer progression and increased folate intake. CONCLUSIONS: Results suggest that the consumption of foods and multivitamins that contain folate is not associated with prostate cancer progression after definitive treatment.
Authors: Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: Daniel M Moreira; Lionel L Bañez; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Int Braz J Urol Date: 2013 May-Jun Impact factor: 1.541
Authors: Piyush K Agarwal; Natalia Sadetsky; Badrinath R Konety; Martin I Resnick; Peter R Carroll Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Adriana C Vidal; Delores J Grant; Christina D Williams; Elizabeth Masko; Emma H Allott; Kathryn Shuler; Megan McPhail; Alexis Gaines; Elizabeth Calloway; Leah Gerber; Jen-Tsan Chi; Stephen J Freedland; Cathrine Hoyo Journal: J Cancer Epidemiol Date: 2012-08-09
Authors: Paul Lochhead; Reiko Nishihara; Zhi Rong Qian; Kosuke Mima; Yin Cao; Yasutaka Sukawa; Sun A Kim; Kentaro Inamura; Xuehong Zhang; Kana Wu; Edward Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Am J Clin Nutr Date: 2015-09-30 Impact factor: 7.045
Authors: Alison J Price; Ruth C Travis; Paul N Appleby; Demetrius Albanes; Aurelio Barricarte Gurrea; Tone Bjørge; H Bas Bueno-de-Mesquita; Chu Chen; Jenny Donovan; Randi Gislefoss; Gary Goodman; Marc Gunter; Freddie C Hamdy; Mattias Johansson; Irena B King; Tilman Kühn; Satu Männistö; Richard M Martin; Klaus Meyer; David E Neal; Marian L Neuhouser; Ottar Nygård; Par Stattin; Grethe S Tell; Antonia Trichopoulou; Rosario Tumino; Per Magne Ueland; Arve Ulvik; Stefan de Vogel; Stein Emil Vollset; Stephanie J Weinstein; Timothy J Key; Naomi E Allen Journal: Eur Urol Date: 2016-04-06 Impact factor: 20.096